Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Altus Pharmaceuticals Reports Dosing First Patient In A Phase 2 Trial Of ALTU-238 For Pediatric Growth Hormone Deficiency
Altus Pharmaceuticals Inc. (NASDAQ: ALTU) announced that patient dosing in its Phase 2 trial for ALTU-238 in growth hormone deficiency pediatric subjects began on June 2, 2009. ALTU-238 is a long-acting, extended-release formulation of recombinant human growth hormone (rhGH, somatropin), which is being developed utilizing Altus" proprietary protein crystallization technology. ALTU-238 is a ready-to-use liquid suspension of crystallized rhGH that preserves the structure of the rhGH molecule without the need for pegylation, polymerization, or encapsulation and enables administration through a fine gauge needle. The Phase 2 ALTU-238 pediatric trial is being conducted in approximately 18 clinical sites in the U.S. and targets enrolling 36 growth hormone deficient pediatric patients. ALTU-238 has been studied in a series of Phase 1 and Phase 2 studies in healthy and GH deficiency adults.

Some Call For More Action At Conclusion Of Pacific Health Summit
Some Pacific Health Summit attendees said more action should have come from the tuberculosis-focused conference, which ended on Thursday in Seattle, Seattle Times" "Business of Giving" blog reports. Paula Akugizibwe, regional treatment advocacy coordinator for the AIDS and Rights Alliance for Southern Africa, said, "The gap between rhetoric and reality grows bigger and bigger," adding that she does not intend to attend anymore global health conferences, where people say the same things, then jet off to another conference and repeat the process.
News of the day
Test For Strep Bacteria In Pregnant Women Misses More Cases Than Expected, Study Shows
A federal recommendation that all pregnant women undergo testing for Group B strep bacteria has helped increase the number of screenings but also has produced a high level of false negatives, according to a study published Thursday in the New England Journal of Medicine, the AP/Newark Star-Ledger reports. Group B strep is a common bacteria in the intestines or lower genital tract. Although it poses no harm to most adults, during delivery it can be spread to infants, who can develop blood infections, pneumonia, meningitis, mental retardation, hearing and vision loss, or death. Problems occur in fewer than one in 3,000 births, but the Centers for Disease Control and Prevention in 2002 issued a recommendation that all pregnant women be tested because of the potential for serious complications. The study is the first research to examine the screening program. The researchers examined data on Group B strep cases in 10 states, finding that 250 infants out of nearly 7,700 were born with the infection. They compared the results with a similar study that was conducted before the CDC recommendations were in place, finding that the screening rate rose from 48% to 85% of pregnant women. The study also found that infant infections from Group B strep declined by 27%.Researchers predicted there would be between 44 and 86 false negatives in full-term infants, based on data from previous studies. However, their results showed about 60% of infected infants -- 116 cases -- were born to women who had tested negative for Group B strep. Researchers noted that the timing of a Group B test might play a role because the infection can come quickly, and tests could have been performed before the bacteria appeared. CDC recommends that pregnant women be screened between 35 and 37 weeks" gestation. CDC researcher Stephanie Schrag, who co-authored the study, said, "Maybe it was a true negative test, and the mother later became colonized" with the bacteria before delivery (Stobbe, AP/Newark Star-Ledger, 6/17).
Mental Health

Sensory Impairment Among Older U.S. Workers Raises Risk Of Injury

A new study analyzing the prevalence of sensory impairment among older U.S. workers found that hearing impairment prevalence was three times that of visual impairment, and that 38 percent of older workers reported experiencing either impairment. Using 1997-2004 national survey data, researchers evaluated the prevalence of sensory impairment among U.S. workers age 65 years and older. Farm operators, mechanics and motor vehicle operators had the highest prevalence of sensory impairment. The study"s authors conclude, "Our findings suggest a need for preventative measures among potentially vulnerable worker groups with sensory impairment. Research is needed to determine whether sensory aids and other workplace accommodations enhance worker productivity and job satisfaction as well as reduce injury risk." American Journal of Public Health


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009